ClinicalTrials.gg
RecruitingNCT07860021Updated Oct 6, 2026

VYVGART (Hytrulo) in Patients With Stiff Person Syndrome (SPS)

A Phase 2/3 interventional study of VYVGART Hytrulo and Hytrulo-placebo (consisting of Hyaluronidase) in Stiff Person Syndrome, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to participants aged 25 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Thomas Jefferson University · Phase 2/3, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
25 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.

Planned enrollment
4th of 10
26 · median 24
Started
2026
the only one that year
Phase 2/3
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
Thomas Jefferson University

Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 2/3, and was the 12th registered.

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Open to participants now

4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 25 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stiff-Person Syndrome with a site in United States, or all of them as a file.
02

Study summary

Stiff Person Syndrome (SPS) is a rare autoimmune disorder, characterized by: a) incapacitating diffuse muscle stiffness prominent in the axial, abdominal and thoracolumbar paraspinal muscles leading to hyperlordosis, difficulty turning and bending; b) painful muscle spasms precipitated by external stimuli with difficulty performing routine daily activities; and c) slow freezing gait with frequent falls and need for walking aids leading to disability. SPS is due to impaired inhibitory GABAergic neurotransmission associated with high-titer IgG antibodies against Glutamic Acid Decarboxylase (GAD), the rate-limiting enzyme for the synthesis of the inhibitory gammaaminobutyric acid (GABA). Although SPS patients respond to IVIg based on the PI's controlled study (NEJM 2001), several patients do not improve, or their response is modest and declines over time, as documented in a longitudinal study of 36 patients followed in our Jefferson clinic; because another controlled study we performed with Rituximab was negative and SPS is a progressive disease, new therapies are needed. Efgartigimod is an FcRn inhibitor that enhances the catabolism of circulating IgG; its subcutaneous, self-administered form, HYTRULO, has been effective and FDA-approved in patients with myasthenia gravis or CIDP poorly responding to IVIg. There is evidence that patients with myasthenia who also had SPS, Hytrulo not only helped their myasthenia but the SPS also impressively improved.

The present study is an investigator- initiated, double-blind, placebo controlled, cross-over, trial in 26 GAD-positive SPS patients poorly responding to available therapies. Patients will be recruited from the large number of patients seen and referred to the PI who is known for his work in SPS and has conducted the 2 previous controlled trials. Although Hytrulo is approved as selfadministered subcutaneous drug with pre-refilled syringes, in this study will be given by a contracted home infusion company once a week to ensure convenience, safety and validity. Patients will be randomized by the Jefferson Pharmacy to receiving Hytrulo or identical hyaluronidase-containing placebo for 3 months; then they will be crossed-over to placebo/Hytrulo for another 3 months. Efficacy will be based on one primary endpoint, the stiffness index, previously validated by the PI, and on two also validated secondary endpoints of time to walk and excitability index. This design provides the statistical power to objectively assess a 25-50% or greater change and objectively determine if Hytrulo offers meaningful benefits in reducing stiffness and spasms, improving gait and increasing quality of life in SPS patients poorly responding to current therapies.

03

Conditions studied

  • Stiff Person Syndrome

Browse trials for

04

Who can participate

Ages eligible
25 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 26 patients age 25-80 with typical SPS as per Dalakas's diagnostic criteria (1,2) poorly or partially responding to IVIg or rituximab with declining benefits, exhibiting significant symptomatology of stiffness, painful muscle spasms, and impaired walking ability will be selected. All enrolled patients will be GAD-ab or Glycin-receptor-antibody-positive and will continue receiving the non- symptomatic drugs, such as diazepam, gabapentin, or baclofen.
  • All selected patients will be among the large number we currently follow in our outpatient clinic or among those being continuously referred for a second opinion or better therapies when unresponsive to current drugs.
  • All patients should be able to provide and willing to travel for scheduled protocol visits.

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if: a) have minimal disease, and less than 1 stiffness index; b) have very severe disease unresponsive to all therapies or non-ambulatory; and c) have paraneoplastic SPS.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    1000 mg efgartigimod PH20 SC

    Drug: VYVGART Hytrulo

  • Placebo comparator
    Hytrulo-placebo (consisting of Hyaluronidase),

    Drug: Hytrulo-placebo (consisting of Hyaluronidase)

Interventions

  • DrugVYVGART Hytrulo

    These patients will receive 1000 mg efgartigimod PH20 SC (VYVGART Hytrulo), every week for 12 weeks (as per Hytrulo's therapeutic guidelines)

  • DrugHytrulo-placebo (consisting of Hyaluronidase)

    Hytrulo-placebo (consisting of Hyaluronidase)

06

What researchers measure

Primary outcomes

  1. Stiffness Index

    The primary endpoint, and has been validated in SPS and used in two previous Dalakas's controlled trials. Change in Stiffness Index measured at monthly visits.

    Time frame: 2 Years

Secondary outcomes

  1. T25-FW (time to walk 25 feet)

    Assessments will be based on the monthly Clinic exams from baseline to Week 12 (monthly visits #1-4,) and after the cross-over from Week 12 to 24 (visits# 5-7).

    Time frame: 2 years

  2. Modified Rankin Scale

    Assessments will be based on the monthly Clinic exams from baseline to Week 12 (monthly visits #1-4,) and after the cross-over from Week 12 to 24 (visits# 5-7).

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Oct 6, 2026
StartEst.
Sep 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860021
Responsible party
marinos dalakas (Professor of Neurology, Director, Neuromuscular Division, Thomas Jefferson University) — Principal investigator
First posted
Oct 6, 2026
Start date
Sep 30, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Marinos Dalakas, M.D., PhD, FAAN
Contact
marinos.dalakas@jefferson.edu
215-955-7865

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion